Anti-cd166 Probody-drug Conjugate Cx-2009 Uses, Dosage, Side Effects and more
Anti-cd166 Probody-drug Conjugate Cx-2009 is under investigation in clinical trial NCT03149549 (PROCLAIM-Anti-cd166 Probody-drug Conjugate Cx-2009: A Trial to Find Safe and Active Doses of an Investigational Drug Anti-cd166 Probody-drug Conjugate Cx-2009 for Patients With Selected Solid Tumors).
| Trade Name | Anti-cd166 Probody-drug Conjugate Cx-2009 |
| Generic | CX-2009 |
| CX-2009 Other Names | Anti-cd166 probody-drug conjugate cx-2009, Praluzatamab ravtansine |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
